Compare Cassava Sciences Inc (FLNA) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Standard Lithium Ltd — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Standard Lithium Ltd trades at $1.59 (market cap $398.07M). The key difference: Standard Lithium Ltd is far larger — about 10.1× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 1,564,155). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Standard Lithium Ltd for 23 Days on average.
| FLNA | SLI | |
|---|---|---|
Market Cap | $39.40M | $398.07M |
Volume | 759,018 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $5.65 |
52-Week Low | $0.68 | $1.61 |
Typical Hold Time | 37 Days | 23 Days |
Enterprise Value | -$43.28M | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
SLI trades at $1.625, down 1.52% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -15.55% and no revenue in 2025, but has beaten EPS estimates in recent quarters. Key developments include progress toward a 2026 final investment decision for its Arkansas lithium project and new offtake agreements.
SLI presents high risk with no current revenue and negative cash flow from operations, but significant upside potential exists if its lithium projects advance. The consensus price target of $3.83 implies 136% upside, supported by 100% buy ratings from analysts. Execution risk on project timelines and funding remains the primary concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
